CEFDINIR

Cefdinir Adverse Events Reported to the FDA Over Time

How are Cefdinir adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Cefdinir, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Cefdinir is flagged as the suspect drug causing the adverse event.

Most Common Cefdinir Adverse Events Reported to the FDA

What are the most common Cefdinir adverse events reported to the FDA?

Diarrhoea	64 (3.68%)
Pyrexia	37 (2.13%)
Rash	37 (2.13%)
Urticaria	32 (1.84%)
Vomiting	30 (1.73%)
Pain	27 (1.55%)
Stevens-johnson Syndrome	26 (1.5%)
Drug Eruption	23 (1.32%)
Liver Disorder	21 (1.21%)
Nausea	20 (1.15%)
Erythema	19 (1.09%)
	Show More
Erythema Multiforme	17 (.98%)
Hepatic Function Abnormal	16 (.92%)
Pruritus	16 (.92%)
Abdominal Pain Upper	15 (.86%)
Abnormal Behaviour	14 (.81%)
Dyspnoea	14 (.81%)
Malaise	14 (.81%)
Pseudomembranous Colitis	14 (.81%)
Aspartate Aminotransferase Increase...	13 (.75%)
Faeces Discoloured	13 (.75%)
Headache	13 (.75%)
Oedema Peripheral	13 (.75%)
Acute Generalised Exanthematous Pus...	12 (.69%)
Alanine Aminotransferase Increased	12 (.69%)
Crying	12 (.69%)
Renal Failure Acute	12 (.69%)
Fatigue	11 (.63%)
Hypersensitivity	11 (.63%)
Abdominal Pain	10 (.58%)
Arthralgia	10 (.58%)
Blood Lactate Dehydrogenase Increas...	10 (.58%)
Completed Suicide	10 (.58%)
Intentional Drug Misuse	10 (.58%)
Rash Generalised	10 (.58%)
Toxic Epidermal Necrolysis	10 (.58%)
Cough	9 (.52%)
Dehydration	9 (.52%)
Lymphocyte Stimulation Test Positiv...	9 (.52%)
Swelling	9 (.52%)
Vanishing Bile Duct Syndrome	9 (.52%)
Convulsion	8 (.46%)
Drug Ineffective	8 (.46%)
Fall	8 (.46%)
Haematochezia	8 (.46%)
Lip Swelling	8 (.46%)
Pharyngeal Oedema	8 (.46%)
Sinusitis	8 (.46%)
Aggression	7 (.4%)
Blood Alkaline Phosphatase Increase...	7 (.4%)
Constipation	7 (.4%)
Drug Rash With Eosinophilia And Sys...	7 (.4%)
Hypoaesthesia	7 (.4%)
Insomnia	7 (.4%)
Joint Swelling	7 (.4%)
Pneumonia	7 (.4%)
Product Quality Issue	7 (.4%)
Renal Impairment	7 (.4%)
Tubulointerstitial Nephritis	7 (.4%)
Anaemia	6 (.35%)
Asthenia	6 (.35%)
Colitis Ulcerative	6 (.35%)
Decreased Appetite	6 (.35%)
Dermatitis Diaper	6 (.35%)
Dizziness	6 (.35%)
Drug Hypersensitivity	6 (.35%)
Drug Interaction	6 (.35%)
Dyspepsia	6 (.35%)
Gamma-glutamyltransferase Increased	6 (.35%)
Gingival Bleeding	6 (.35%)
Incorrect Dose Administered	6 (.35%)
Medication Error	6 (.35%)
Pain In Extremity	6 (.35%)
Platelet Count Decreased	6 (.35%)
Respiratory Arrest	6 (.35%)
Rhinorrhoea	6 (.35%)
Screaming	6 (.35%)
Sepsis	6 (.35%)
Upper Respiratory Tract Inflammatio...	6 (.35%)
Agitation	5 (.29%)
Blood Glucose Increased	5 (.29%)
Chills	5 (.29%)
Clostridial Infection	5 (.29%)
Condition Aggravated	5 (.29%)
Dysuria	5 (.29%)
Ear Infection	5 (.29%)
Feeling Abnormal	5 (.29%)
Fungal Infection	5 (.29%)
Haemolytic Anaemia	5 (.29%)
Heart Rate Increased	5 (.29%)
Nasopharyngitis	5 (.29%)
Oedema	5 (.29%)
Periodontitis	5 (.29%)
Pharyngitis	5 (.29%)
Pleural Effusion	5 (.29%)
Product Odour Abnormal	5 (.29%)
Rash Pruritic	5 (.29%)
Serum Sickness	5 (.29%)
Swelling Face	5 (.29%)
Toxic Skin Eruption	5 (.29%)
Viral Infection	5 (.29%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Cefdinir, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cefdinir is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Cefdinir

What are the most common Cefdinir adverse events reported to the FDA?

Epidermal And Dermal Conditions	224 (12.89%)
Gastrointestinal Signs	116 (6.67%)
Gastrointestinal Motility And Defec...	83 (4.78%)
Infections - Pathogen Unspecified	60 (3.45%)
Neurological	59 (3.39%)
Respiratory	59 (3.39%)
Hepatic And Hepatobiliary	48 (2.76%)
Body Temperature Conditions	39 (2.24%)
Angiedema And Urticaria	35 (2.01%)
Hematology Investigations	34 (1.96%)
Hepatobiliary	32 (1.84%)
	Show More
Allergic Conditions	29 (1.67%)
Medication Errors	29 (1.67%)
Bacterial Infectious	28 (1.61%)
Renal Disorders	25 (1.44%)
Joint	23 (1.32%)
Cardiac And Vascular Investigations	21 (1.21%)
Oral Soft Tissue Conditions	20 (1.15%)
Therapeutic And Nontherapeutic Effe...	20 (1.15%)
Enzyme	19 (1.09%)
Injuries	19 (1.09%)
Product Quality Issues	19 (1.09%)
Dental And Gingival Conditions	17 (.98%)
Musculoskeletal And Connective Tiss...	17 (.98%)
Psychiatric And Behavioural Symptom...	16 (.92%)
Urinary Tract Signs	16 (.92%)
Headaches	15 (.86%)
Ocular Infections, Irritations And ...	14 (.81%)
Upper Respiratory Tract Disorders	14 (.81%)
Gastrointestinal Hemorrhages	13 (.75%)
Nephropathies	13 (.75%)
Sleep Disorders	13 (.75%)
Anemias Nonhemolytic And Marrow Dep...	12 (.69%)
Renal And Urinary Tract Investigati...	12 (.69%)
Suicidal And Self-injurious Behavio...	12 (.69%)
Electrolyte And Fluid Balance Condi...	11 (.63%)
Hemolyses And Related Conditions	11 (.63%)
Viral Infectious	11 (.63%)
Anxiety Disorders	10 (.58%)
Metabolic, Nutritional And Blood Ga...	10 (.58%)
Psychiatric	10 (.58%)
Bile Duct	9 (.52%)
Movement Disorders	9 (.52%)
Muscle	9 (.52%)
Personality Disorders	9 (.52%)
Seizures	9 (.52%)
Bronchial Disorders	8 (.46%)
Chemical Injury And Poisoning	8 (.46%)
Lifestyle Issues	8 (.46%)
Physical Examination Topics	8 (.46%)
Skin Appendage Conditions	8 (.46%)
Vision	8 (.46%)
Appetite And General Nutritional	7 (.4%)
Deliria	7 (.4%)
Gastrointestinal Inflammatory Condi...	7 (.4%)
Lower Respiratory Tract Disorders	7 (.4%)
Vulvovaginal Disorders	7 (.4%)
Administration Site Reactions	6 (.35%)
Cardiac Disorder Signs	6 (.35%)
Communication Disorders	6 (.35%)
Eye	6 (.35%)
Fungal Infectious	6 (.35%)
Gastrointestinal Conditions	6 (.35%)
Gastrointestinal Stenosis And Obstr...	6 (.35%)
White Blood Cell	6 (.35%)
Cardiac Arrhythmias	5 (.29%)
Decreased And Nonspecific Blood Pre...	5 (.29%)
Hematological And Lymphoid Tissue T...	5 (.29%)
Pleural	5 (.29%)
Head And Neck Therapeutic Procedure...	4 (.23%)
Mood Disorders	4 (.23%)
Neurological, Special Senses And Ps...	4 (.23%)
Vascular	4 (.23%)
Vascular Hypertensive	4 (.23%)
Anal And Rectal Conditions	3 (.17%)
Central Nervous System Vascular	3 (.17%)
Connective Tissue Disorders	3 (.17%)
Coronary Artery	3 (.17%)
External Ear Disorders	3 (.17%)
Pericardial	3 (.17%)
Tongue Conditions	3 (.17%)
Water, Electrolyte And Mineral	3 (.17%)
Acid-base	2 (.12%)
Autoimmune	2 (.12%)
Cardiac Valve	2 (.12%)
Economic And Housing Issues	2 (.12%)
Encephalopathies	2 (.12%)
Gastrointestinal Tract Disorders Co...	2 (.12%)
Gastrointestinal Vascular Condition...	2 (.12%)
Mental Impairment	2 (.12%)
Microbiology And Serology	2 (.12%)
Procedural And Device Related Injur...	2 (.12%)
Protein And Chemistry Analyses	2 (.12%)
Spinal Cord And Nerve Root	2 (.12%)
Toxicology And Therapeutic Drug Mon...	2 (.12%)
Urolithiases	2 (.12%)
Vascular Hemorrhagic	2 (.12%)
Ancillary Infectious Topics	1 (.06%)
Arteriosclerosis, Stenosis, Vascula...	1 (.06%)
Aural	1 (.06%)
Bone Disorders	1 (.06%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Cefdinir, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Cefdinir is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.